Palisade Bio, Inc.
PALI Healthcare Biotechnology
Palisade Bio, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $250,000.00. In the quarter to June 2026, revenue grew 19,900.0%, EPS grew 91.4% and free cash flow fell 318.4%, each against the same quarter a year earlier. Revenue growth for three consecutive years; insiders bought in the last twelve months.
Follow PALI
A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash and Short Term Investments |
20.20 | 11.67 | 5.79 | 5.11 | 0.71 | 10.50 | 12.38 | 12.43 | 9.82 | 133.39 |
Receivables |
0.06 | 0.37 | 0.36 | 0.02 | 0.06 | — | — | — | — | — |
Total current assets |
20.90 | 12.45 | 6.51 | 5.65 | 0.90 | 11.51 | 14.73 | 13.33 | 10.49 | 134.22 |
Property, Plant, Equpment (Net) |
0.27 | 0.17 | 0.09 | 0.04 | 0.01 | 0.00 | 0.01 | 0.01 | 0.00 | — |
Long-term receivables |
0.42 | 0.37 | 0.30 | — | — | — | — | — | — | — |
Goodwill and Intangible Assets (Total) |
0.99 | 0.88 | 0.76 | 0.67 | — | — | — | — | — | — |
Long-term assets (Other) |
0.02 | 0.01 | 0.02 | 0.23 | 0.03 | 0.89 | 0.72 | 0.52 | 0.30 | 0.12 |
Total non-current assets |
1.70 | 1.44 | 1.18 | 0.94 | 2.12 | 1.01 | 1.03 | 0.72 | 0.39 | 0.12 |
Total Assets |
22.60 | 13.88 | 7.68 | 6.58 | 3.02 | 12.51 | 15.76 | 14.05 | 10.88 | 134.34 |
Accounts Payable |
2.34 | 0.88 | 0.83 | 0.82 | 2.54 | 1.32 | 1.76 | 0.70 | 1.11 | 0.77 |
Accrued Expenses |
0.85 | 0.42 | — | 0.14 | 4.33 | 0.97 | 1.06 | 1.61 | 1.96 | 3.49 |
Current Part of Debt |
3.71 | — | — | 0.03 | 1.05 | 0.09 | 0.09 | 0.16 | 0.08 | 0.38 |
Other current liabilities |
0.43 | 0.22 | 0.22 | 0.26 | — | — | — | — | — | — |
Total current liabilities |
7.33 | 1.51 | 1.05 | 1.22 | 8.08 | 2.50 | 3.01 | 2.59 | 3.24 | 4.64 |
Long Term Debt (Total) |
— | — | — | 0.15 | 0.09 | — | — | — | — | — |
Non-current Liabilities (Other) |
3.94 | 3.85 | 0.58 | 0.08 | 1.83 | 2.65 | 0.06 | 0.06 | 0.15 | 0.33 |
Total non-current liabilities |
3.94 | 3.85 | 0.58 | 0.23 | 2.04 | 2.65 | 0.27 | 0.15 | 0.15 | 0.33 |
Total liabilities |
11.27 | 5.37 | 1.63 | 1.46 | 10.12 | 5.15 | 3.28 | 2.74 | 3.39 | 4.96 |
Additional Paid In Capital |
204.24 | 217.05 | 219.65 | 227.07 | 51.40 | 102.00 | 121.64 | 132.81 | 143.41 | 280.51 |
Preferred Stock (Total) |
0.01 | 0.01 | 0.01 | 0.00 | 9.50 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Common Stock (Net) |
0.11 | 0.15 | 0.01 | 0.04 | 0.03 | 0.00 | 0.03 | 0.01 | 0.03 | 1.59 |
Retained Earnings |
(193.03) | (208.70) | (213.62) | (221.98) | (68.03) | (94.64) | (109.19) | (121.51) | (135.94) | (152.72) |
Common Equity (Total) |
11.32 | 8.51 | 6.04 | 5.12 | (16.60) | 7.36 | 12.48 | 11.31 | 7.49 | 129.38 |
Shareholders Equity (Total) |
11.33 | 8.52 | 6.05 | 5.13 | (7.10) | 7.37 | 12.48 | 11.31 | 7.49 | 129.38 |
Shareholders Equity and Liabilities (Total) |
22.60 | 13.88 | 7.68 | 6.58 | 3.02 | 12.51 | 15.76 | 14.05 | 10.88 | 134.34 |
Shares (Common) |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 0.20 | 0.62 | 2.77 | 159.44 |
Shares (Preferred) |
0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 0.01 | 0.01 | 0.20 | 0.20 | 0.20 |
Shareholders Equity (Tangible) |
10.34 | 7.63 | 5.29 | 4.46 | (7.10) | 7.37 | 12.48 | 11.31 | 7.49 | 129.38 |
Net Debt |
(16.49) | (11.67) | (5.79) | (4.93) | 0.43 | (10.41) | (12.29) | (12.27) | (9.74) | (133.00) |
Total Debt |
3.71 | — | — | 0.18 | 1.14 | 0.09 | 0.09 | 0.16 | 0.08 | 0.38 |